Biotech startups that raised Series A in The Netherlands
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Matisse Pharmaceuticals | Geleen | Series A | $16.0M | 2026-09-17 |
| Kynexis | Naarden | Series A | $112.3M | 2026-08-19 |
| Qorium | Maastricht | Series A | $25.5M | 2025-11-11 |
| VSPARTICLE | Delft | Series A | $7.1M | 2024-08-08 |
| MindAffect | Nijmegen | Series A | $1.2M | 2024-04-29 |
| Flindr Therapeutics | Amsterdam | Series A | $21.4M | 2024-04-24 |
| VectorY | Amsterdam | Series A | $138.0M | 2023-11-13 |
| Synerkine Pharma | Utrecht | Series A | $5.6M | 2023-10-12 |
8 rows of the CSV in 5 of its 18 columns.
- The 31 biotech startups in The Netherlands whose last round is Series A have raised $807.3M in total.
- 4 of them closed their most recent round in the last 12 months, $198.6M combined.
- The largest of those rounds is Kynexis' $112.3M Series A, dated August 2026.
- The most recent is Anaheim Bio's $44.9M Series A on 5 November 2026.
- Brightlands Venture Partners is an investor in 2 of them, more than any other fund.
- Health care is the most common other sector, with 24 companies (77%).
- 23% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (66% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
7 of 31| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Matisse Pharmaceuticals | Matisse Pharmaceuticals develops therapies for sepsis and septic shock by targeting cytotoxic histones. | Biotech | Geleen | Series A | $16.0M | 2026-09-17 | $22.0M | Brightlands Venture Partners, Chemelot Ventures, Limburg Business Development Fund (LBDF) | 11 to 50 | 2014 |
| Kynexis | Kynexis develops precision medicine treatments for cognitive impairment associated with schizophrenia. | Biotech | Naarden | Series A | $112.3M | 2026-08-19 | $173.3M | Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures | 11 to 50 | 2023 |
| Qorium | Qorium makes reinvented real leather materials. | Biotech | Maastricht | Series A | $25.5M | 2025-11-11 | $28.6M | Sofinnova Partners, Brightlands Venture Partners | 11 to 50 | 2021 |
| VSPARTICLE | VSPARTICLE makes nanoparticle generators for sensors, batteries, catalysis, solar cells, and other uses. | Biotech | Delft | Series A | $7.1M | 2024-08-08 | BlueYard Capital, MIT delta v, NordicNinja VC +2 | 11 to 50 | 2014 | |
| MindAffect | MindAffect develops brain-computer interfaces for medical applications. | Artificial intelligence | Nijmegen | Series A | $1.2M | 2024-04-29 | NLC, Wasteland Investments, Barco Limpo | 1 to 10 | 2017 | |
| VectorY | VectorY develops gene therapies for central nervous system, somatic, and muscle diseases. | Biotech | Amsterdam | Series A | $138.0M | 2023-11-13 | $175.6M | Insight Partners, Benhamou Global Ventures, Forbion Capital Partners +2 | 51 to 100 | 2020 |
| Synerkine Pharma | Synerkine Pharma develops fusion proteins for treating chronic pain. | Biotech | Utrecht | Series A | $5.6M | 2023-10-12 | InnovationQuarter, Thuja Capital, Flerie Invest +1 | 1 to 10 | 2009 |
Table 1. Biotech startups that raised Series A in The Netherlands: the 7 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 31.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kynexis | Kynexis develops precision medicine treatments for cognitive impairment associated with schizophrenia. | Biotech | Naarden | Series A | $112.3M | 2026-08-19 | $173.3M | Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures | 11 to 50 | 2023 |
| 2 | Matisse Pharmaceuticals | Matisse Pharmaceuticals develops therapies for sepsis and septic shock by targeting cytotoxic histones. | Biotech | Geleen | Series A | $16.0M | 2026-09-17 | $22.0M | Brightlands Venture Partners, Chemelot Ventures, Limburg Business Development Fund (LBDF) | 11 to 50 | 2014 |
Table 2. Biotech startups that raised Series A in The Netherlands: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Brightlands Venture Partners | Venture capital firm | Geleen, The Netherlands | 2 | 6% | 1 | Matisse Pharmaceuticals |
| 2 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 2 | 6% | 1 | Kynexis |
| 3 | Limburg Business Development Fund (LBDF) | Corporate venture arm | Maastricht, The Netherlands | 1 | 3% | 1 | Matisse Pharmaceuticals |
| 4 | Chemelot Ventures | Micro VC fund | Urmond, The Netherlands | 1 | 3% | 1 | Matisse Pharmaceuticals |
| 5 | Sunstone Life Science Ventures | Micro VC fund | Copenhagen, Denmark | 1 | 3% | 1 | Kynexis |
| 6 | Ysios Capital | Venture capital firm | San Sebastian, Spain | 1 | 3% | 1 | Kynexis |
| 7 | Sofinnova Partners | Venture capital firm | Paris, France | 1 | 3% | ||
| 8 | Plural Platform | Venture capital firm | London, United Kingdom | 1 | 3% | ||
| 9 | BlueYard Capital | Venture capital firm | Berlin, Germany | 1 | 3% | ||
| 10 | Hermann Hauser Investment | Venture capital firm | Innsbruck, Austria | 1 | 3% | ||
| 11 | NordicNinja VC | Venture capital firm | London, United Kingdom | 1 | 3% | ||
| 12 | MIT delta v | Startup accelerator | Cambridge, United States | 1 | 3% | ||
| 13 | Wasteland Investments | Venture capital firm | 1 | 3% | |||
| 14 | Barco Limpo | 1 | 3% | ||||
| 15 | NLC | Startup accelerator | Amsterdam, The Netherlands | 1 | 3% |
Table 3. Biotech startups that raised Series A in The Netherlands: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 24 | 77% | $711.7M |
| Software | 3 | 10% | |
| Hardware | 2 | 6% | |
| Energy | 1 | 3% | |
| Artificial intelligence | 1 | 3% |
Table 4. Biotech startups that raised Series A in The Netherlands by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 31 | 100% | $8.1M |
Table 5. Biotech startups that raised Series A in The Netherlands by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Utrecht | 4 | 13% |
| Maastricht | 4 | 13% |
| Amsterdam | 4 | 13% |
| Leiden | 3 | 10% |
| Nijmegen | 2 | 6% |
| The Hague | 2 | 6% |
| Geleen | 1 | 3% |
| Naarden | 1 | 3% |
| Delft | 1 | 3% |
| Rotterdam | 1 | 3% |
| Eindhoven | 1 | 3% |
| Bilthoven | 1 | 3% |
Table 6. Biotech startups that raised Series A in The Netherlands by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 25% | $44.9M |
| September 2026 | 1 | 25% | $16.0M |
| August 2026 | 1 | 25% | $112.3M |
| December 2025 | 1 | 25% | $25.3M |
Table 7. Biotech startups that raised Series A in The Netherlands: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 3 | 10% | $173.3M |
| 2025 | 3 | 10% | $117.8M |
| 2024 | 3 | 10% | $29.7M |
| 2023 | 4 | 13% | $214.4M |
| 2022 | 2 | 6% | $39.1M |
| 2021 | 1 | 3% | $17.3M |
Table 8. Biotech startups that raised Series A in The Netherlands by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 2 | 6% |
| 2020 to 2022 | 5 | 16% |
| 2015 to 2019 | 11 | 35% |
| 2010 to 2014 | 9 | 29% |
| Before 2010 | 4 | 13% |
Table 9. Biotech startups that raised Series A in The Netherlands by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 8 | 28% |
| 11 to 50 | 19 | 66% |
| 51 to 100 | 2 | 7% |
Table 10. Biotech startups that raised Series A in The Netherlands by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in The Netherlands. On 16 November 2026 that is 31 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 7 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 31 rows: 3 have no round amount, 0 no city and 11 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in The Netherlands whose last round is Series A are on the list?
- 31, in the file dated 16 November 2026. 4 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 31 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.